DOC Pharma Official

What DOC Pharma Official does

DOC Pharma Official (legal entity: Doc Generici S.r.l.) is an Italian generic pharmaceutical company headquartered in Milan, founded in 1996 following Italian Law No. 425/1996, which legalized equivalent medicines. Originally established by Chiesi Farmaceutici, Zambon, and Apotex, the company has passed through four private equity ownerships and is currently majority-owned by TPG Capital (since 2022). DOC Pharma operates an asset-light model, outsourcing manufacturing to a network of 69 CDMO partners across Europe (39 in Italy, 73% of products made domestically) while retaining control over raw materials, formulation specifications, and distribution.

The company markets a portfolio of 640+ products across 13 therapeutic areas, including cardiovascular, gastrointestinal, anti-infective, neurological, respiratory, musculoskeletal, and dermatological medications, plus a specialized ophthalmology franchise (Doc Ofta) supported by two patented delivery platforms: the Pactive self-preserving bottle and the Ophthalmic Squeeze Dispenser (OSD). Revenue is generated through unit-priced sales of Class A (NHS-reimbursable) generics, OTC products, medical devices, and nutraceuticals, with 89% of products eligible for NHS reimbursement and the remainder sold through private pharmacy channels.

Distribution flows through the Italian pharmacy network, supported by a field sales force targeting physicians and pharmacists via the Medikey healthcare professional portal. DOC Pharma is the #2 player in the Italian Class A equivalent drug market (~19% share) and the 8th largest pharmaceutical company in Italy by value, with IQVIA 2023 ex-factory revenue of EUR 299 million and 70M+ packs sold. Geographic presence extends to Italy, Portugal, and Czech Republic following the 2024 acquisition of Muscoril from Sanofi, with active serial-acquisition activity (Medivis 2022, Muscoril 2024, Geopharma 2025) under TPG ownership driving portfolio and geographic expansion.

Name

DOC Pharma Official

Legal name

Doc Generici S.r.l.

Website

https://docpharma.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

251–500 employees

Short description

DOC Pharma Official (formerly DOC Generici) is an Italy-based generic pharmaceutical company offering 640+ products across 13 therapeutic areas, serving patients, pharmacists, and physicians primarily through the Italian NHS, with EUR 299M in 2023 revenue and a #2 position in Italian Class A generics.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceuticals
• Bioequivalent medicines
• Ophthalmology products
• Ethical drugs
• Medical devices

Headquarters

HQ city

Milan

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: DOC Pharma generates revenue through the manufacture and sale of generic pharmaceutical products including ethical drugs (prescription), over-the-counter medications, medical devices, and nutraceuticals. Products are distributed through pharmacies and healthcare facilities across Italy and select international markets.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

DOC Pharma (formerly DOC Generici) is an Italian generic pharmaceutical company that develops, markets, and distributes bioequivalent generic medicines, medical devices, food supplements, and over-the-counter products across 13 therapeutic areas. With 640+ products and 70M+ packs sold in 2023, the company specializes in cardiovascular, gastrointestinal, anti-infective, neurological, respiratory, musculoskeletal, and ophthalmology products, operating through CDMO partners for manufacturing while maintaining control of quality and distribution.

Product overview

DOC Pharma is an Italian generic pharmaceutical company offering a comprehensive portfolio of over 640 products across 13 therapeutic areas. The product portfolio is organized into three main categories: Ethical Drugs (prescription generic medications), Other Products (medical devices, food supplements, and cosmetics), and Over-the-Counter drugs. The company operates specialized business units including Doc Ofta for ophthalmology. Ethical drugs span cardiovascular, gastrointestinal/metabolic, anti-infective, antineoplastic/immunomodulating, dermatological, haematological, neurological, systemic hormonal, respiratory, musculoskeletal, genitourinary, and other therapeutic areas. The ophthalmology portfolio includes branded products like Arnistil, Renova (Tre, Lipo, Oxi) for dry eye treatment, plus food supplements (Macula360, Vitreolene, Resolvis Capsule) and medical devices. Distribution focuses on Italy and Europe, with 73% of products manufactured in Italy and 69 manufacturing sites across Europe.

Differentiator

Problem solved

Functional benefit

Brands

• Doc Ofta: Business Unit dedicated to patients and physicians offering comprehensive support to the world of ophthalmology, strengthening market presence through acquisition of Medivis in 2022.
• DOC
• BIMADOC
• Renova
• Arnistil
• Muscoril
• Uripyr

Products and services

• Ethical Drugs (Farmaci Etici) Prescription generic medications across 13 therapeutic areas including cardiovascular, gastrointestinal/metabolic, anti-infective, neurological, respiratory, musculoskeletal, dermatological, hematological, genitourinary, ophthalmology, systemic hormonal, antineoplastic/immunomodulating, and other therapeutic categories. Sold through Italian pharmacy network and reimbursed by NHS.
• Doc Ofta (Ophthalmology Business Unit) Dedicated business unit for ophthalmology serving patients and physicians with comprehensive support including ethical drugs, medical devices, food supplements, and ophthalmic products. Includes proprietary Pactive and OSD technologies for preservative-free formulations.
• Muscoril Muscle relaxant pharmaceutical product (tiocolchicoside) acquired from Sanofi in 2024 for the musculoskeletal portfolio in Italy, Portugal, and Czech Republic.
• Arnistil Sterile moisturizing ophthalmic solution based on 0.2% hyaluronic acid and 0.1% arnica extract without preservatives, packaged in patented self-preserving Pactive bottle for irritated and red eyes.
• Renova product line Sterile ophthalmic solution brand including Renova (sodium hyaluronate 0.4% with levo-carnitine), Renova Tre (trehalose 2.0% and hyaluronic acid 0.25%), Renova Lipo (sodium hyaluronate 0.4% with lipids for night-time use), and Renova Oxi (sodium hyaluronate 0.2% with floral distilled water). Preservative-free formulations for relief of dry and irritated eye symptoms.
• BIMADOC Ophthalmic product containing Bimatoprost for glaucoma treatment.
• Uripyr Food supplement based on calcium pyruvate, uridine 5'-monophosphate and Vitamin C that contributes to normal function of the immune system and cell protection from oxidative stress.
• Farmaci da banco (OTC) - Muscoril Dolore Self-medication over-the-counter products accessible without prescription, including Muscoril Dolore (diclofenac diethylamine) for pain relief.
• Ophthalmology Food Supplements (Macula360, Vitreolene, Forvista, Vitreo360) Food supplements for ocular health including Macula360 (citicoline, lutein, zeaxanthine, resveratrol for retinal support), Vitreolene (L-Lysine, Vitamin C, hyaluronic acid, hydrolyzed collagen for vitreous health), Forvista (24 components including lutein, zeaxanthine, lycopene for comprehensive eye support), and Vitreo360 (hydrolyzed collagen, glucosamine for vitreous aging).
• Ophthalmology Medical Devices (Septavis, Blefadine, Lidcure HA) Medical devices for eye and eyelid hygiene including Septavis (sodium hypochlorite solution with sterile gauzes), Blefadine (sterile cotton pads with tea tree oil, hyaluronic acid and aloe), and Lidcure HA (sterile cotton pads with hyaluronic acid for periocular area hygiene).
• DOC Product Catalog Platform Digital platform enabling browsing and access to DOC's full product catalog across ethical drugs, OTC, medical devices, food supplements, and cosmetics.
• Healthcare Professional Portal (Operators Area) Reserved area for healthcare professionals providing access to product information, RCP (summary of product characteristics), scientific documentation, and professional services. Access via Medikey credentials.

Quantifiable outcome

• IQVIA 2023 ex-factory revenue of EUR 299 million, ranking 8th in Italian pharmaceutical market
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and major.

• GeopharmacoreStrategic or Co-development Partner · 1 January 2025Acquisition of Geopharma's product portfolio, a company specializing in nutraceuticals for the osteoarticular field, expanding DOC's product offerings.
• SanofimajorStrategic or Co-development Partner · 24 April 2024Strategic acquisition of Muscoril®, a muscle relaxant drug, from Sanofi. The agreement covers Italy, Portugal, and the Czech Republic, strengthening DOC's musculoskeletal portfolio and market position.
• MedivismajorStrategic or Co-development Partner · 1 January 2022Acquisition of Medivis product portfolio in 2022, strengthening DOC's presence in the ophthalmology market and enabling investment in R&D for eye care products.
• CDMOs (Contract Development and Manufacturing Organizations)coreTechnology or IntegrationDOC does not own production facilities. The company partners with the best CDMOs in Italy and Europe for manufacturing. Quality is ensured through rigorous controls of raw materials, production plants, and distribution chains.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Sandoz (Novartis): One of the world's largest generic and biosimilar manufacturers, with a significant European footprint. Direct competitor in the Italian generic market and a model for what a scaled, pan-European generic platform can become.
• Krka: Slovenian generic pharmaceutical manufacturer with strong presence in Central and Eastern Europe. Comparable to DOC in its broad generic portfolio across cardiovascular, CNS, and other therapeutic areas, with similar CDMO-style vertical integration.
• Aurobindo Pharma: Indian-headquartered global generic pharmaceutical manufacturer with significant European operations. Competes with DOC through API and finished generic drug supply, particularly in low-cost generic categories.
• Teva Pharmaceutical Industries: Global generic pharmaceutical leader with a strong Italian presence. Directly competes with DOC Pharma in Class A generic drugs across multiple therapeutic areas, including cardiovascular, CNS, and anti-infectives. Comparable in product breadth and payor-driven model.
• EG (Eurogenerici): Italian generic pharmaceutical company and direct domestic competitor to DOC in the Class A generic segment. Closely comparable in product portfolio, NHS reimbursement model, and Italian pharmacy distribution.
• Stada Arzneimittel: European-focused generic and consumer healthcare company, PE-owned through Bain and Cinven. Closely comparable to DOC in business model: generics across multiple therapeutic areas, asset-light CDMO reliance, and European geographic focus.
• Viatris: Formed from Mylan and Upjohn, Viatris is a major global generic and specialty pharmaceutical company with strong European distribution. Competes directly with DOC in Italian Class A generics and adjacent specialty categories.
• Zentiva: European generic pharmaceutical company headquartered in Prague, recently owned by Sanofi and Advent. Directly comparable to DOC in pan-European generic drug distribution, especially in Italy and Czech Republic where DOC also operates.

Others

• Apotex: Canadian generic pharmaceutical company and one of DOC's three founding shareholders (1996). Industry peer in global generic manufacturing, with historical DNA shared through DOC's founding structure.

Broad incumbents

• Chiesi Farmaceutici: Italian multinational pharmaceutical company focused on specialty care (respiratory, neonatology, rare diseases). Comparable to DOC as a fellow Italian pharma major and one of DOC's three founding shareholders, though Chiesi focuses on branded specialty rather than generics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@DOCpharmaofficial
• Facebookfacebook.com/docpharmaofficial
• LinkedInlinkedin.com/company/doc-pharma-official

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DOC Pharma Official